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Background/Aims: Ischemia-modiﬁ  ed albumin (IMA) levels 
have been shown to correlate with the severity of liver failure 
in adults. However, the role of IMA levels has not been evalu-
ated in children with chronic liver disease (CLD). We analyzed 
the clinical significance of IMA levels in children with CLD. 
Methods: Thirty-three children with CLD and 33 healthy chil-
dren were included in the study. Blood was collected to ana-
lyze biochemical parameters, oxidant status, and IMA. Liver 
biopsies were re-evaluated for liver fibrosis; severe fibrosis 
(SF) was deﬁ  ned as ﬁ  brosis stage ≥4. Results: The IMA and 
and IMA to albumin ratios (IMARs) were signiﬁ  cantly higher in 
children with CLD than in those without (IMA: 0.545±0.095 
vs 0.481±0.062, p=0.003; IMAR: 0.152±0.046 vs 
0.126±0.018, p=0.04). The IMAR was positively correlated 
with the pediatric end-stage liver disease score (p=0.03, 
r=0.503) and fibrosis score (p=0.021, r=0.400). Patients 
with SF had higher IMARs compared to patients with mild 
ﬁ  brosis (0.181±0.056 vs 0.134±0.025, p=0.003). The area 
under the receiver operation curve (AUROC) for predicting SF 
was 0.78 (p=0.006). Using a cutoff ratio value of 0.140, the 
sensitivity and specificity were 84% and 70%, respectively. 
The AUROC for predicting the need for liver transplantation 
and/or death was 0.82 (p=0.013). With a cutoff value of 
0.156, the sensitivity and speciﬁ  city was 83% and 82%, re-
spectively. Kaplan-Meier analysis revealed increased morbid-
ity and/or mortality in the group with an IMAR>0.156 (50% 
vs 4.3%, p=0.005). Conclusions: IMARs have been shown to 
provide important clues in predicting the ﬁ  brosis stage of the 
disease and determining the outcome in children with CLD. 
(Gut Liver 2012;6:92-97)
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INTRODUCTION
Albumin is the major plasma protein that is primarily synthe-
sized in the liver.
1 Its concentration is reduced in patients with 
chronic liver failure, and with the advanced cirrhosis the effec-
tive plasma volume decreased as a result of hypoalbuminemia 
and splenic vasodilatation. Albumin is mainly used in patients 
with chronic liver diseases (CLD) to replenish the circulating vol-
ume, to prevent the post-paracenthesis circulatory disturbance 
and to reduce mortality associated with spontaneous bacterial 
peritonitis.
2,3
The amino terminal end of albumin molecule appears to be 
the primary site for binding transition metal ions, cobalt and 
nickel. This site of the albumin is susceptible to biochemical 
degradation, and is less stable under environmental changes.
4 
Under various conditions such as ischemia, hypoxia, acidosis 
and superoxide-radical injury, the binding capacity of albumin 
for metals is decreased and generates a metabolic variant of 
protein with reduced transition metal binding. This change is 
quantifiable and commonly known as ischemia modified albu-
min (IMA).
4-7
High serum IMA level has been proposed as a sensitive mark-
er for the diagnosis of myocardial ischemia before the onset of 
irreversible cardiac injury in patients presenting with typical 
acute chest pain.
7 However, IMA level is also known to increase 
in other ischemic conditions, and in diseases such as advanced 
cancer, systemic sclerosis, intrauterine disorders and end-stage 
renal disease due to free radical productions.
7,8 Elevated IMA 
level has been used to assess the subclinical vascular disease in 
patients with type 2 diabetes mellitus.
9
Recently, albumin functions have been studied in patients 
with decompensated cirrhosis in an adult study; and found that 
albumin functions are compromised in advanced cirrhosis. Ad-Cakir M, et al: IMAR Levels in Chronic Liver Disease  93
ditionally, they claimed that serum IMA level (expressed as an 
albumin ratio and used as a marker of albumin function) cor-
relate with the disease severity and may have prognostic use in 
acute-on-chronic liver failure.
10 However, the role of IMA has 
not been evaluated in children with CLD. Therefore, we aimed 
to analyze 1) serum IMA level, 2) their clinical significance, 3) 
correlation with laboratory findings including liver function 
tests and oxidant status, 4) association with liver histology, and 
5) impact on outcome in children with CLD.
MATERIALS AND METHODS
Thirty-nine consecutive children with newly diagnosed CLD 
were enrolled into the study. The diagnosis of CLD was based on 
clinical, laboratory, radiological, and histopathological findings. 
Patients were excluded if they received albumin infusion within 
the 1 month prior to entry in the study, had clinical or laborato-
ry findings of infection and hepatorenal syndrome, had hepatic/
extrahepatic malignancy and had vascular disease or thrombo-
sis (n=6). Finally 33 children (mean age, 9.4±5.4 years and 17 
F, 16 M) with chronic liver disease were included in the study, 
and 33 age and sex matched healthy children were (mean age, 
9.3±5.5 years and 17 F, 16 M) served as control group. Twenty-
one children (63.6%) had metabolic liver diseases including Wil-
son’s disease in 11, glycogen storage disease in 5, tyrosinemia 
in 2 and other metabolic liver diseases in 3. Six patients (18.1%) 
had cholestatic liver diseases, 3 (9.1%) had autoimmune liver 
diseases and 3 (9.1%) had cryptogenic cirrhosis (Table 1). Three 
patients had acute-on-chronic liver failure due to acute variceal 
bleeding in two and large volume paracenthesis in the other. 
Peripheral venous blood of the participants was collected 
from the subjects at the time of inclusion into the study and 
used for routine biochemical parameters, oxidant status, and 
IMA. Routine biochemical parameters including total protein, 
albumin, creatinine, liver enzymes, bilirubin and international 
normalized ratio (INR) levels were studied enrolment. The rest 
of the plasma stored at -80°C for studying to IMA levels and 
oxidant status at the end of the study. Clinical findings of the 
patients including presence of malnutrition, portal hyperten-
sion, ascites and encephalopathy were recorded, and Child-Pugh 
score and pediatric end-stage liver disease (PELD) score were 
calculated.
11,12
IMA level (reduced cobalt to albumin binding capacity) was 
analyzed using the rapid and colorimetric method developed by 
Bar-Or et al.
5 Two hundred microliter (μL) of patient serum was 
placed into glass tubes and 50 μL of 0.1% CoCl2+6H2O (Sigma) 
added. After gentle shaking, the mixture was left undisturbed 
for 10 minutes to ensure sufficient cobalt albumin binding. 
Then, 50 μL of 1.5 mg/mL dithiothreitol (DTT) was added as a 
coloring agent. After 2 minutes, 1 mL of 0.9% NaCl was added 
to quench the reaction. A control sample was prepared for every 
sample. At the DTT addition stage, 50 μL of distilled water was 
used instead of 50 μL of 1.5 mg/mL DTT to obtain a control 
sample without DTT. Sample absorbencies were analyzed at 470 
nm using a spectrophotometry (Shimadzu UV1601; Shimadzu, 
Tokyo, Japan). Color formation in specimens with DTT was 
compared with color formation in the control tubes, and the re-
sults were expressed as absorbance units.
Total oxidant status (TOS) of serum was determined us-
ing a novel automated measurement method as previously 
described.
13 Serum TOS levels were calculated in μmol H2O2 
equivalent/L. Total antioxidant status (TAS) of the serum was 
determined using a novel-automated measurement method, 
developed by Erel.
14 Serum TAS levels were calculated in mmol 
Trolox equivalent/L. The TOS/TAS ratio was used as the oxida-
tive stress index (OSI). To perform the calculation, the units of 
TAC, mmol Trolox equivalent/L, was converted to mmol Trolox 
equivalent/L, and OSI was calculated as follows: OSI=[(TOS, 
μmol H2O2 equivalent/L)/(TAS, μmol Trolox equivalent/L)×100]. 
Table 1. Demographic, Clinical, and Laboratory Findings in Patients 
with CLD and in the Control Group
Parameter
Patients with CLD
(n=33)
Control 
group
(n=33)
Age, yr 9.4±5.4 9.3±5.5
Gender, F/M 17/16 17/16
Primary diagnosis
   Metabolic liver disease
   Cholestatic liver disease
   Autoimmune hepatitis
   Cryptogenic cirrhosis 
21 (63.6)
6 (18.1)
3 (9.1)
3 (9.1)
Encephalopathy 5 (15.1)
Ascites 4 (12.1)
Portal hypertension 6 (18.1)
Malnutrition 8 (24.2)
Child-Pugh score (A, B, C) 22, 6, 5 (66.7, 18.1, 15.2)
PELD score (range) 6.6±12.1 (-8 to 43)
Fibrosis score 2.7±1.8
Severe fibrosis 13 (39.4)
Fatty changes 12 (36.3)
ALT, IU/L 240.5±340.6 N/A
Albumin, mg/dL 3.6±0.5* 3.8±0.4
̈
Hypoalbuminemia, <3.5 mg/dL 8 (24.2)
̉ 1 (3)
§
Bilirubin, mg/dL 2.7±4.5 N/A
TAS, mmol Trolox equiv./L 19.6±12.2 N/A
TOS, μmol H2O2 equiv./L 7.7±6.9 N/A
OSI, arbitrary unit 0.7±1 B/A 
Data are presented as mean±SD (range) or number (%).
CLD, chronic liver disease; PELD, pediatric end-stage liver disease; 
ALT, alanine aminotransferase; TAS, total antioxidant status; TOS, 
total oxidant status; OSI, oxidative stress index; N/A: non available. 
*
,̈p=0.039; 
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Liver biopsies of the patients were re-evaluated for the liver 
fibrosis by the pathologist (U.C) according to modified ISHAK 
score (0 to 6) as defined by Standish et al.
15 Severe fibrosis was 
defined as fibrosis stage ≥4. Fatty changes were classified ac-
cording Schwimmer et al.
16 In all patients with CLD, percutane-
ous liver biopsy was done.
Serum IMA and IMA/albumin ratio (IMAR) were compared 
between the patients and control group. Then, clinical and labo-
ratory factors that may affect the serum IMA and IMAR levels 
were evaluated in children with CLD. IMAR is used in order to 
eliminate the effect of reduced albumin concentrations, com-
mon in children with CLD, on serum IMA level. We found out 
if there was correlation between histopathological findings and 
serum IMAR levels. Additionally, we also analyzed the effect of 
serum IMAR level on the outcome of the patients. 
Informed consent for participating in the study was obtained 
from parents of all cases and the ethics committee of the Karad-
eniz Technical University Faculty of Medicine, approved this 
study.
All the data were described as mean and standard deviation. 
Differences between groups were calculated using an indepen-
dent samples t-test for the normally distributed data and the 
Mann-Whitney test for data not normally distributed. Correla-
tions between variables were calculated using linear regression. 
The area beneath the receiver operating characteristics curves 
was used to discriminative power of the IMA, IMAR in the 
diagnosis of severe fibrosis. Values of p<0.05 were considered 
significant. 
RESULTS
Serum IMA and IMAR levels were significantly high in 
children with CLD compared to healthy controls (0.545±0.095 
vs 0.481±0.062, p=0.003; and 0.152±0.046 vs 0.126±0.018, 
p=0.04, respectively) (Table 2). No correlation was determined 
between serum IMA level and age (p=0.845, r=0.341), and no 
difference was established between the genders. Additionally, 
no correlation was determined between albumin and IMA level 
(p=0.339, r=-0.123).
Clinical findings and their relation with serum IMAR level 
were evaluated and found that patients with portal hypertension 
(n=6), encephalopathy (n=5), cholestasis (n=11), and malnutri-
tion (n=8) had higher IMAR level than the others (0.230±0.044 
vs 0.135±0.023, p=0.0001; 0.229±0.049 vs 0.139±0.029, 
p=0.0001; 0.183±0.061 vs 0.137±0.026, p=0.004; 0.197±0.059 
vs 0.136±0.026, p=0.003, respectively). 
Correlation of serum IMAR level with the laboratory findings 
is shown in Table 3. No correlation was found between serum 
alanine aminotransferase (ALT), INR, TAS, TOS, and OSI levels 
and serum IMAR level. Only bilirubin level was significantly 
correlated with serum IMAR level (p=0.003, r=0.503). 
Serum IMAR level was significantly high in patients with Child-
Pugh score B and C compared to patients with Child-Pugh score A 
(0.185±0.059 vs 0.136±0.027, p=0.002). IMAR level was also posi-
tively correlated with PELD score (p=0.03, r=0.503) (Fig. 1). 
Fig. 1. The correlation of serum ischemia modified albumin ratios 
(IMARs) with the pediatric end-stage liver disease (PELD) score 
(p=0.03, r=0.503).
Table 2. The Serum IMA Levels and IMARs in Children with CLD and 
in the Control Group
Parameter
Patients with CLD
(n=33)
Control group
(n=33)
p-value
IMA (ABSU)
   Mean 
   Median
   SD
   Range
0.545 
0.550
0.095
0.330-0.755
0.481 
0.480
0.062
0.323-0.595
0.003
IMAR
   Mean 
   Median
   SD
   Range
0.152
0.139
0.046
0.09-0.290
0.126 
0.127
0.018
0.09-0.170
0.004
CLD, chronic liver disease; IMA, ischemia modified albumin; ABSU, 
absorbance unit; SD, standard deviation; IMAR, ischemia modified 
albumin ratio.
Table 3. The Correlation of IMARs with the Laboratory Findings
Parameter
IMAR level
r p-value
ALT -0.121 0.502
Bilirubin  0.503 0.003
INR  0.561 0.413
TAS -0.065 0.744
TOS -0.155 0.390
OSI -0.008 0.966
IMAR, ischemia modified albumin ratio; ALT, alanine aminotrans-
ferase; INR, international normalized ratio; TAS, total antioxidant 
status; TOS, total oxidant status; OSI, oxidative stress index; r, cor-
relation coefficient.Cakir M, et al: IMAR Levels in Chronic Liver Disease  95
IMAR level was positively correlated with fibrosis score 
(p=0.021, r=0.400), and patients with severe fibrosis (n=13) had 
higher IMAR level compared to patient with mild fibrosis (n=20) 
(0.181±0.056 vs 0.134±0.025, p=0.003). The area under the 
receiver operation curve (AUROC) for predicting severe fibrosis 
was 0.78 (p=0.006; 95% confidence interval [CI], 0.61 to 0.95) 
(Fig. 2). With a cutoff ratio value of 0.140, the sensitivity and 
specificity were 84% and 70%, respectively. Other biochemical 
parameters such as serum ALT, bilirubin, TAS, and TOS levels 
did not showed any significantly difference between the patients 
with severe and mild fibrosis. On the other hand, no significant 
difference was determined in serum IMAR level between the 
patients with (n=12, 36.3%) and without (n=21, 63.7%) fatty 
changes (0.165±0.066 vs 0.145±0.029, p=0.245).
In long term follow-up (14.2±7.2 months); 5 (15.1%) of the 
33 patients underwent liver transplantation, and 1 patient 
(3%) died without liver transplantation. Comparison of these 
6 patients with the other patients revealed higher IMAR level 
(0.209±0.063 vs 0.140±0.031; p=0.011). The AUROC for pre-
dicting need for liver transplantation and/or death was 0.82 
(p=0.013; 95% CI, 0.60 to 1.04) (Fig. 3). With a cutoff value of 
0.156, the sensitivity and specificity were 83% and 82%, respec-
tively. Kaplan-Meier analysis revealed increased morbidity and/
or mortality in the group with an IMAR>0.156 (50% vs 4.3%, 
p=0.005) (Fig. 4). The AUROC for predicting need for liver trans-
plantation and/or death for PELD score and Child-Pugh score 
was 0.84 and 0.62, respectively.  
DISCUSSION
This is the first study that evaluates the serum IMA and IMAR 
levels in patients with pediatric CLD, and revealed that IMA and 
IMAR levels were higher in these patients compared to healthy 
subjects. Elevation of IMAR, a marker of albumin function, and 
impairment of liver functions in patients with CLD not only 
decreases the effective circulation volume in association with 
hypoalbuminemia, but also declines the removal of toxic me-
tabolites due to impairment in albumin functions. 
Higher level of IMAR in decompensated cirrhotic children 
(with cholestasis and portal hypertension) may contribute to 
accumulation of toxic metabolites (tryptophan, endogenous 
benzodiazepines, bile acids, and fatty acids) in these patients, 
and may aggravate the development of hepatic encephalopathy. 
In addition, despite the low number of cases, IMAR level was 
higher in patients with encephalopathy compared to the other 
patients. Treatment regimens that aim to improve the albumin 
functions in patients with hepatic encephalopathy may be effec-
tive on the clinical improvement and outcome. However, Jalan 
et al.
10 demonstrated that the application of Molecular Adsor-
bents Recirculating System had no effect on albumin functions 
Fig. 3. The receiver operation curve of serum ischemia modified albu-
min ratio (IMAR)  to examine its predictive use for assessing the need 
for liver transplantation and/or mortality (area under the receiver 
operation curve [AUROC], 0.82; p=0.013; 95% confidence interval, 
0.60-1.04; best cutoff value, 0.156).
Fig. 2. The receiver operation curve of serum ischemia modified 
albumin ratio (IMAR) to examine its predictive use for assessing se-
vere fibrosis (area under the receiver operation curve [AUROC], 0.78; 
p=0.006; 95% confidence interval, 0.61-0.95; best cutoff value, 0.140).
Fig. 4. The Kaplan-Meier analysis of outcomes based on a cutoff val-
ue of 0.156. Morbidity and/or mortality were significantly different 
between the children with chronic liver disease and the control group 
(50% vs 4.3%, p=0.005).96  Gut and Liver, Vol. 6, No. 1, January 2012
in patients with advanced cirrhosis and suggested that the im-
pairment in albumin functions in such patients was irreversible.
IMAR level was observed to be correlated with Child-Pugh 
score and PELD score. Similar results were reported by Jalan et 
al.
10 and Klammt et al.
17 Apart from this, no correlation was de-
termined between INR and serum IMAR level. Moreover, other 
clinical studies about IMA have suggested that elevated IMA is 
more associated with superoxide radicals forming as a result of 
increasing oxidizing capacity and decreasing antioxidizing ca-
pacity; but no correlation was determined between IMAR level 
and TAS and TOS in our study.
18 This shows that elevated IMAR 
level in CLD is more associated with primary liver function than 
micro-environmental changes. 
One of the interesting results of our study is that there is a 
correlation between liver fibrosis and serum IMAR level. In ad-
dition, an IMAR level above 0.140 has been shown to be a good 
marker of severe fibrosis (fibrosis stage ≥4) (AUROC, 0.78; sensi-
tivity and specificity were 84% and 70%, respectively). In recent 
years, the usefulness of non-invasive markers for determining 
liver fibrosis has been investigated because of complications, al-
beit rarely, following liver biopsy and difficulties in determining 
whole fibrosis with a little biopsy material. These have included 
radiological methods (FibroScan, Echosens, Paris, France; and 
MR elastography), indirect serological markers (AST/ALT ratio, 
AST/platelet ratio, Prothrombin, γGT, and Apolipoprotein A1 
(PGA) index, FibroIndex, FIB-4 index, Fibrotest, and ActiTest) 
and direct serological markers (matrix deposition and matrix 
degradation markers).
19 IMAR is correlated with hepatic disease 
severity, not affected by other parameters, cost-effective and 
measured easily made it acceptable as a fibrosis marker. But this 
usefulness will become clearer with further studies with larger 
numbers of patient group with homogeneous etiology. 
Another result of our study is that serum IMAR level is a 
good predictor of need for liver transplantation and/or death 
even in metabolic liver diseases. The most important parameter 
on this subject is PELD score, but there are some problems about 
the usefulness of PELD especially in patients with liver tumors, 
metabolic liver diseases and patients with malnutrition.
20 The 
usefulness of IMAR on these subjects needs to be shown with 
wider studies using multiple serial measurements rather than a 
single measurement.
Limitations in our study are that 1) our patient group was 
small, 2) the primary etiology for the CLD was heterogeneous, 
3) most of our study group had very early stage patients (Child-
Pugh score A), and 4) a single measurement was used instead of 
serial measurements.  
In conclusion, IMAR level is investigated for the first time in 
children with CLD, and has been shown to provide important 
clues in predicting the fibrosis stage of the disease, and deter-
mining the outcome. Our study suggests that albumin therapy 
in liver failure can be used not only as a volume replacement 
agent but also in the removal of toxic metabolites. Additionally, 
further prospective studies are needed with larger patient num-
bers to analyze the effect of liver transplantation on albumin 
functions in children with CLD. 
CONFLICTS OF INTEREST
No potential conflict of interest relevant to this article was 
reported.
REFERENCES
1. Quinlan GJ, Martin GS, Evans TW. Albumin: biochemical proper-
ties and therapeutic potential. Hepatology 2005;41:1211-1219.
2. Arroyo V. Human serum albumin: not just a plasma volume ex-
pander. Hepatology 2009;50:355-357.
3. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin 
on renal impairment and mortality in patients with cirrhosis and 
spontaneous bacterial peritonitis. N Engl J Med 1999;341:403-
409.
4.  Collinson PO, Gaze DC. Ischaemia-modified albumin: clinical util-
ity and pitfalls in measurement. J Clin Pathol 2008;61:1025-1028.
5. Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin 
binding and its potential as a marker for myocardial ischemia-a 
preliminary report. J Emerg Med 2000;19:311-315.
6. Roy D, Quiles J, Gaze DC, Collinson P, Kaski JC, Baxter GF. Role 
of reactive oxygen species on the formation of the novel diagnos-
tic marker ischaemia modified albumin. Heart 2006;92:113-114.
7. Sbarouni E, Georgiadou P, Voudris V. Ischemia modified albumin 
changes: review and clinical implications. Clin Chem Lab Med 
2011;49:177-184.
8. Turedi S, Cinar O, Yavuz I, et al. Differences in ischemia-modified 
albumin levels between end stage renal disease patients and the 
normal population. J Nephrol 2010;23:335-340.
9.  Dahiya K, Aggarwal K, Seth S, Singh V, Sharma TK. Type 2 diabe-
tes mellitus without vascular complications and ischemia modified 
albumin. Clin Lab 2010;56:187-190.
10.  Jalan R, Schnurr K, Mookerjee RP, et al. Alterations in the 
functional capacity of albumin in patients with decompensated 
cirrhosis is associated with increased mortality. Hepatology 
2009;50:555-564.
11. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. 
Transection of the oesophagus for bleeding oesophageal varices. 
Br J Surg 1973;60:646-649.
12.  McDiarmid SV, Merion RM, Dykstra DM, Harper AM. Selection 
of pediatric candidates under the PELD system. Liver Transpl 
2004;10(10 Suppl 2):S23-S30.
13.  Erel O. A new automated colorimetric method for measuring total 
oxidant status. Clin Biochem 2005;38:1103-1111.
14. Erel O. A novel automated method to measure total antioxidant 
response against potent free radical reactions. Clin Biochem 
2004;37:112-119.
15.  Standish RA, Cholongitas E, Dhillon A, Burroughs AK, Dhillon AP. Cakir M, et al: IMAR Levels in Chronic Liver Disease  97
An appraisal of the histopathological assessment of liver fibrosis. 
Gut 2006;55:569-578.
16.  Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling 
C. Prevalence of fatty liver in children and adolescents. Pediatrics 
2006;118:1388-1393.
17. Klammt S, Mitzner S, Stange J, et al. Albumin-binding function 
is reduced in patients with decompensated cirrhosis and correlates 
inversely with severity of liver disease assessed by model for end-
stage liver disease. Eur J Gastroenterol Hepatol 2007;19:257-263.
18. Gunduz A, Mentese A, Turedi S, et al. Serum ischaemia-modified 
albumin increases in critical lower limb ischaemia. Emerg Med J 
2008;25:351-353.
19.  Carey E, Carey WD. Noninvasive tests for liver disease, fibro-
sis, and cirrhosis: is liver biopsy obsolete? Cleve Clin J Med 
2010;77:519-527. 
20. Wiesner RH, McDiarmid SV, Kamath PS, et al. MELD and PELD: 
application of survival models to liver allocation. Liver Transpl 
2001;7:567-580.